Characteristics and survival outcomes in patients with hormonosensitive metastatic prostate cancer in an oncologic centre in Medellín, Colombia
Article Sidebar
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Societal impact
Main Article Content
Abstract
Objective: To characterize patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated in an outpatient oncology care institution in Medellín-Colombia.
Methods: An observational, retrospective study with survival analysis. Patients with mHSPC who initiated treatment at our institution after December 2013 were included. Progression-free survival (PFS), including radiographic or serological progression, and overall survival (OS) were calculated with the Kaplan-Meier method. Subgroup analyses were carried out according to received therapy for mHSPC and tumour burden. Differences were evaluated through the log-rank test. A p-value <0.05 was considered statistically significant.
Results: Data of 111 patients with mHSPC were analysed. The median follow-up was 32.2 months (IQR:15.9-47.5). The median age was 68.9 years (IQR:63.4-78.2). High tumour burden accounted for 73.9 %. The most used treatment modalities included ADT monotherapy (30.6 %), and ADT in combination with docetaxel (34.2 %). Median PFS and OS was 24.2 (95 %CI:19.0-29.5) and 53.5 months (95 % CI:45.3-61.7), respectively. In low metastatic volume patients, median PFS in the ADT monotherapy group and ADT plus other therapy group was 22.5 (CI95 %: 11.0-34.0) and 30.5 months (CI95 %:8.7-52.3), respectively (P=0.035). There was no significant difference between groups in OS.
Conclusion: Comparable survival rates between our population and those described in controlled clinical trials were found.
Article Details
References
Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today (version 1.1). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024,74(3):229-263.
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024, 74(1):12-49.
Fondo Colombiano de Enfermedades de Alto Costo. Cuenta de Alto Costo (CAC). Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2023; Bogotá, D.C. 2024.
Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 2016, 19:395–7.
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022, 20: 1288-1298.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015, 373:737–46.
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013, 14:149–58.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016, 387:1163–77.
Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016,17:243–56.
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017, 377:338–51.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017, 377:352–60.
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019, 37:2974–86.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019, 38:121–31.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022, 386:1132–42.
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022, 399:1695–707.
Wang X, Hershman DL, Abrams JA, Feingold D, Grann VR, Jacobson JS, et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer. 2007, 97:1606–12.
Yekedüz E, McKay RR, Gillessen S, Choueiri TK, Ürün Y. Visceral metastasis predicts response to new hormonal agents in metastatic castration-sensitive prostate cancer. Oncologist. 2023, 28:596–603.
EAU 2022: State of the Art Lecture: Synchronous vs Metachronous mHSPC: What makes the difference? Disponible en: https://www.urotoday.com/conference-highlights/eau-annual-congress-2022/eau-2022-prostate-cancer/138189-eau-2022-state-of-the-art-lecture-synchronous-vs-metachronous-mhspc-what-makes-the-difference.html